What’s Next for Patient Access: Reducing Friction Through Connected, Scalable Strategies

As specialty medications grow more complex and the healthcare landscape continues to evolve, biopharma organizations are facing increased friction across the drug lifecycle, from launch through long-term patient support. Addressing these challenges requires more than incremental change. It demands connected, scalable strategies that reduce complexity and improve how access processes support patients throughout the therapy journey.

In the videos below, CoverMyMeds leaders share their perspectives on how the industry can move beyond fragmented systems and manual processes toward more integrated approaches. From building connected ecosystems to embedding access and affordability directly into provider workflows, these conversations highlight what it takes to improve visibility, reduce delays and better support patients across their journey.

What Specialty Access Looks Like When It’s Built to Scale

Fragmentation across the patient access journey continues to create inefficiencies, delays and administrative burden for providers and biopharma teams alike. In this video, Miranda Delatore, DNP, RN, NEA-BC, Vice President, Product, explores how a more connected ecosystem can help address these challenges by bringing together eligibility, prior authorization and patient support into a unified approach. By enabling real-time information exchange and improving visibility across stakeholders, connected workflows can reduce rework, streamline processes and help reduce time to therapy.

Built for What’s Next: The Future of Access and Affordability

As the pace and complexity of the healthcare environment increase, solutions that add steps or sit outside existing workflows are no longer sustainable. In this video, Nicole Eckl, Vice President, Biopharma Sales and Megan Wetzel, Vice President, Product, Access and Affordability, discuss how innovation must be embedded directly into the tools providers already use to meaningfully reduce friction. From improving affordability access upfront to supporting patients across the full product lifecycle, they emphasize the importance of scalable, flexible strategies that evolve with brand needs, helping patients access and continue therapy in an increasingly complex system.